
Fortress Biotech, Inc. (FBIO) earnings
- Healthcare
- NASDAQ
- Market cap$63M
Latest result
8 days ago+14.8%EPS Beat
2026-11-13Q3 FY2026BMO
- EPS
- Reported / estimate-0.23 / -0.27
- Revenue
- $19.2M / $21.6M-11.0%
Stock reaction
-5.53%
-5.16 pts vs SPY
Session 2026-11-13
Next report
No scheduled report date right now.
Recent quarters
Latest 12 quartersRevenue and stock reaction
Beat in 5 of 6 quarters with a measured stock reaction · beat then fell 4 · average move (last 8) ±5.7%
| Quarter | EPSReported / estimate | RevenueReported / estimate | Reaction |
|---|---|---|---|
Q3 FY2026 2026-11-13 | -0.23 / -0.27 +14.8% | $19.2M / $21.6M -11.0% | -5.53% -5.16 pts vs SPY |
Q2 FY2026 2026-08-13 | -0.08 / -0.20 +60.0%†¶ | $18.7M / $18.3M +2.3%¶ | -1.68% -1.48 pts vs SPY Session 2026-08-14 |
Q1 FY2026 2026-05-14 | 2.82 / -0.22 +1381.8%†¶ | $16.0M / $16.3M -1.8%¶ | +4.78% +5.99 pts vs SPY Session 2026-05-15 |
Q1 FY2026 2026-03-31 | -0.21 / 0.42 -150.0%‡¶ | $16.1M / $26.2M -38.5%¶ | -11.47% -12.22 pts vs SPY Session 2026-04-01 |
Q3 FY2025 2025-11-14 | 0.11 / -0.43 +125.6%†¶ | $17.6M / $21.0M -16.1%¶ | +5.22% +5.24 pts vs SPY |
Q2 FY2025 2025-08-14 | -0.46 / -0.31 -48.4%¶ | $16.4M / $21.0M -21.9%¶ | +8.16% +8.40 pts vs SPY Session 2025-08-15 |
Q1 FY2025 2025-05-21 | -1.03 / -0.44 -134.1%‡¶ | — / — | +1.76% +1.73 pts vs SPY Session 2025-05-22 |
Q4 FY2024 2025-03-27 | -0.53 / -0.79 +32.9%¶ | — / — | -6.94% -4.92 pts vs SPY Session 2025-03-28 Company's usual timing |
Q3 FY2024 2024-11-14 | -0.76 / -0.27 -181.5%†¶ | $14.6M / $15.6M -6.1%¶ | -8.92% -7.64 pts vs SPY Session 2024-11-15 |
Q2 FY2024 2024-08-13 | -0.73 / -1.32 +44.7%¶ | $14.9M / $14.8M +0.9%¶ | -1.09% -1.41 pts vs SPY Session 2024-08-14 |
Q1 FY2024 2024-05-15 | -1.03 / -2.03 +49.3%¶ | $13.0M / $14.1M -7.8%¶ | +1.15% +1.36 pts vs SPY Session 2024-05-16 |
Q4 FY2023 2024-03-28 | -0.53 / -1.97 +73.1%¶ | — / — | -0.50% -0.33 pts vs SPY Session 2024-04-01 |
Reported / estimate
- Q3 FY2026 · 2026-11-13-5.53%EPS-0.23 / -0.27+14.8%Revenue$19.2M / $21.6M-11.0%
- Q2 FY2026 · 2026-08-13-1.68%EPS-0.08 / -0.20+60.0%†¶Revenue$18.7M / $18.3M+2.3%¶
- Q1 FY2026 · 2026-05-14+4.78%EPS2.82 / -0.22+1381.8%†¶Revenue$16.0M / $16.3M-1.8%¶
- Q1 FY2026 · 2026-03-31-11.47%EPS-0.21 / 0.42-150.0%‡¶Revenue$16.1M / $26.2M-38.5%¶
- Q3 FY2025 · 2025-11-14+5.22%EPS0.11 / -0.43+125.6%†¶Revenue$17.6M / $21.0M-16.1%¶
- Q2 FY2025 · 2025-08-14+8.16%EPS-0.46 / -0.31-48.4%¶Revenue$16.4M / $21.0M-21.9%¶
- Q1 FY2025 · 2025-05-21+1.76%EPS-1.03 / -0.44-134.1%‡¶Revenue— / —
- Q4 FY2024 · 2025-03-27-6.94%EPS-0.53 / -0.79+32.9%¶Revenue— / —Company's usual timing
- Q3 FY2024 · 2024-11-14-8.92%EPS-0.76 / -0.27-181.5%†¶Revenue$14.6M / $15.6M-6.1%¶
- Q2 FY2024 · 2024-08-13-1.09%EPS-0.73 / -1.32+44.7%¶Revenue$14.9M / $14.8M+0.9%¶
- Q1 FY2024 · 2024-05-15+1.15%EPS-1.03 / -2.03+49.3%¶Revenue$13.0M / $14.1M-7.8%¶
- Q4 FY2023 · 2024-03-28-0.50%EPS-0.53 / -1.97+73.1%¶Revenue— / —
- †Unusually large: likely a one-off gain or charge, so not comparable with consensus
- ‡A surprise beyond ±100% is usually a one-off item or a different basis, so it is left out of averages
- ¶Estimate recorded after the releaseNo estimate was saved before the results came out, so the surprise is measured against an estimate recorded after the release.
- Company's usual timingNo release time is on record for this report, so the reaction uses the company's usual slot (before the open or after the close) from most of its past reports.
Reaction is the close of the reacting session versus the previous close. The gap to SPY is in percentage points.